CORONA vs RUBICON: Stock Comparison
RUBICON RESEARCH is the larger company by market capitalisation. CORONA REMEDIES shows a lower P/E, a higher ROE and a higher dividend yield, while RUBICON RESEARCH shows faster revenue growth and a higher net margin. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.
Metric snapshot
CORONA leads 9; RUBICON leads 4 of 13
Interactive comparison
Compare the numbers that shape the decision
Every row uses its own scale. Switch lenses to compare like with like.
Valuation lens
What price are you paying?
✓ marks the usual favourable reading; it is not a recommendation.
Key Differences
Each difference is a single, relative reading — StockeZee does not name an overall winner.
Profile
| Metric | CORONA | RUBICON |
|---|---|---|
| Sector | — | Healthcare |
| Industry | — | Pharmaceuticals |
Price
| Metric | CORONA | RUBICON |
|---|---|---|
| Live Price | ₹2,152.5 | ₹1,791.8 |
| Day Change | 0.42% | 1.42% |
| Volume | 6,298 | 1.17 L |
| 52-Week High | ₹2,292.4 | ₹1,899 |
| 52-Week Low | ₹1,336.6 | ₹570.75 |
| Distance from 52W High | -6.1% | -5.65% |
Valuation
| Metric | CORONA | RUBICON |
|---|---|---|
| Market Cap | ₹13,087 Cr | ₹29,632 Cr |
| P/E Ratio | 66.97x | 102.12x |
| P/B Ratio | 17.84x | 22.84x |
| EPS | ₹9.83 | ₹4.99 |
| Book Value | ₹122.12 | ₹77.93 |
| Dividend Yield | 0.46% | 0.08% |
Growth
| Metric | CORONA | RUBICON |
|---|---|---|
| Revenue Growth (TTM YoY) | 0% | 43.5% |
| EPS Growth (TTM YoY) | 0% | 96.6% |
| Qtr Sales Growth | 0% | -19.95% |
| Qtr Profit Growth | -0.02% | -2.75% |
Profitability & Leverage
| Metric | CORONA | RUBICON |
|---|---|---|
| ROE | 24.28% | 19.14% |
| ROCE | 20.94% | 20.49% |
| Net Margin | 13.19% | 13.48% |
| Operating Margin | 15.89% | 20.68% |
| Debt to Equity | 0.19x | 0.2x |
Shareholding
As of Jun 2026 • change vs previous quarter| Metric | CORONA | RUBICON |
|---|---|---|
| Promoter Holding | 69% | 23.93%▼ 0.04 pp |
| FII Holding | 3.63%▲ 1.38 pp | 7.52%▼ 0.02 pp |
| DII Holding | 12.9%▲ 5.88 pp | 9.43%▼ 0.59 pp |
| Public Holding | 14.48%▼ 7.26 pp | 23.3%▲ 0.72 pp |
How to Read This Comparison
Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.
Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: CORONA REMEDIES and RUBICON RESEARCH.
Related Comparisons
Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.